VOR

Vor Biopharma Inc.

NasdaqGSUSDEQUITY DELAYED

23.03

▼ 0.03 (0.14%)

MARKET · —

Price

Open

23.07

Prev close

23.07

Day high

23.86

Day low

23.07

Volume

613.76K

Market cap

—

P/E (TTM)

—

52W range

6.50 – 50.20

Trailing performance

Price return · vs SPY

Returnvs SPY

+1.43% +2.8%

+23.08% +19.3%

+55.32% +52.2%

+72.40% +61.3%

YTD

+78.59% +66.3%

-46.91% -66.9%

-60.00% -134.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

23.19

-0.68% from price

SMA 20

22.36

+4.48% from price

SMA 50

19.39

+20.50% from price

SMA 100

17.27

+33.39% from price

SMA 200

15.20

+53.70% from price

EMA 12

22.90

+0.59% from price

EMA 26

21.73

+6.01% from price

EMA 50

20.05

+14.86% from price

RSI (14)

62.1

Neutral

MACD (12,26,9)

1.17

Hist -0.12

ATR (14)

1.21

5.16% of price

Realised vol 30D

68.0%

Annualised

Bollinger upper

25.05

20, 2σ

Bollinger lower

19.66

20, 2σ

50 / 200 cross

Golden

19.39 vs 15.20

Trend bias

Above 200

+53.70%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.47

More volatile than market

Correlation to SPY

0.17

Largely independent

Realised vol 30D

68.0%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-85.9%

Peak to trough

Max drawdown 5Y

-99.2%

Peak to trough

ATR 14

1.21

5.16% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 23.03

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

VOR · links out to the publisher

Wedbush Adjusts Price Target on Vor Biopharma to $27 From $18, Keeps Neutral Rating MT Newswires · 11d ago Vor Biopharma Shares Drop After Q2 Results MT Newswires · 11d ago Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · 11d ago Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 19d ago Vor Bio Appoints David Zaccardelli to Board of Directors GlobeNewswire · 46d ago Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next Simply Wall St. · 53d ago Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China GlobeNewswire · 75d ago Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China GlobeNewswire · 75d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.